Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer

Pancreatic cancer is a lethal disease with poor prognosis. Gemcitabine has been the first line systemic treatment for pancreatic cancer. However, the rapid development of drug resistance has been a major hurdle in gemcitabine therapy leading to unsatisfactory patient outcomes. With the recent renewe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ru, Lai, Lisa A, Sullivan, Yumi, Wong, Melissa, Wang, Lei, Riddell, Jonah, Jung, Linda, Pillarisetty, Venu G., Brentnall, Teresa A., Pan, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554139/
https://www.ncbi.nlm.nih.gov/pubmed/28801576
http://dx.doi.org/10.1038/s41598-017-08436-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554139/
https://www.ncbi.nlm.nih.gov/pubmed/28801576
http://dx.doi.org/10.1038/s41598-017-08436-6

Ejemplares similares